



## **ASX Announcement and Media Release**

**Friday 30 June, 2017**

**SciGen Ltd**

### **CHANGE IN THE BOARD OF DIRECTORS**

#### **RESIGNATION OF DIRECTOR & CORPORATE SECRETARY**

The Board of Directors of SciGen Limited (ASX: SIE) (the “**SciGen**”) announce the retirement of Ms. Jenny Low as Senior Vice President of the Company effective 30 June 2017. Following her retirement, Ms. Low has resigned as a Director and Company Secretary at the close of the Annual General Meeting on the same date. Ms. Low has been an integral part of the Company and has been with the Company since its inception. The Board thanks Ms. Low for her distinguished tenure (as CFO and later as Senior Vice President) and her numerous contributions to SciGen and wishes her well.

#### **About SciGen**

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes therapeutics such as rhuman Growth Hormone, rhuman Insulin and GCSF.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen’s major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with

marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, China and Philippines, distribution channels in China, India, Malaysia, Myanmar, Pakistan, Bangladesh, Thailand and Indonesia and a contract manufacturer in Poland, Bioton S.A.

<b>For further information:</b> Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: <a href="mailto:gdunlop@scigen.com.au">gdunlop@scigen.com.au</a>	Adam Polonek CFO SciGen Ltd +65 6779 6638